Should I buy BioCryst stock in 2025?

What is BioCryst?

How much is the BioCryst stock?

The price of BioCryst stock is rising this week. As of now, the share price stands at $10.88, a gain of $0.32 (+3.03%) over the last 24 hours and up 8.04% for the week. BioCryst’s market capitalisation is $2.277 billion, with an average three-month trading volume of 97.34 million shares. The forward P/E ratio is 62.11 (current P/E not applicable due to reported losses), there is no dividend yield, and the stock’s beta is 1.08. With ongoing advances in specialised medicines and a solid market position in Ireland and beyond, BioCryst’s shares may appeal to investors seeking growth opportunities, though one should be aware of its potential volatility.

Our full analysis on the BioCryst stock

Having thoroughly examined BioCryst Pharmaceuticals’ most recent financial statements in conjunction with its robust multi-year share performance, we have triangulated quantitative fundamentals, technical market data, and sector positioning, supported by our proprietary selection algorithms. The synthesis of these diverse analytical layers highlights several compelling bullish signals that merit close attention from investors seeking growth in the dynamic biotechnology arena. So, why might BioCryst stock once again become a strategic entry point into the biopharmaceutical sector heading into 2025?

Recent Performance and Market Context

BioCryst Pharmaceuticals (NASDAQ: BCRX) has enjoyed a remarkable twelve months, with its share price advancing a substantial 76.91% year-on-year as of May 30, 2025, closing at $10.88—just below its 52-week high of $11.11. Over the last six months alone, the stock has surged 45.07%, significantly outpacing most biotech peers and indicating a persistent accumulation phase among institutional and retail investors alike.

Catalysts behind this rally are multifaceted. Most notably, BioCryst’s flagship product, ORLADEYO, continues to deliver robust revenue growth, underpinned by expanded reimbursement across Western Europe and upwardly revised 2025 sales forecasts. The biotech sector at large is thriving on the back of heightened global awareness of rare diseases and innovation-friendly regulatory momentum, providing a supportive macroeconomic backdrop. In an Irish and broader European context—where access to novel therapies remains a key focus—BioCryst’s strategic expansion appears especially well timed.

Furthermore, sectoral sentiment has shifted towards optimism, favouring high-growth, revenue-expansion biotech names. With a market capitalisation now standing at $2.277 billion, BioCryst commands increasing recognition as a leader within its specialty niche, supporting a compelling momentum narrative for late 2024 and beyond.

Technical Analysis

A close technical reading of BCRX as of May 30, 2025, further underscores the stock’s strength. The 14-day RSI sits at 66.62—neutral-to-bullish and approaching the classic overbought threshold without breaching it, a hallmark of a sustainable, non-excessive uptrend. The MACD (12,26,9) of 0.59 generates a clear buy signal, confirming continued positive momentum.

These averages are all trending upwards, and the price’s sustained trading above each average reflects robust market demand. Importantly, the $10.21 support level is acting as a strong technical floor, while resistance at $10.90 has repeatedly been probed—suggesting that a breakout could position the stock for rapid appreciation, especially as the sector’s bullish structure persists.

The aggregate technical consensus from leading analytics providers is thus firmly in the “strong buy” camp, pointing to the possibility that BCRX is entering a new medium-term bullish phase.

Fundamental Analysis

• Revenue expansion: FY 2024 total revenues grew by 36% YoY to $450.7 million, with flagship product ORLADEYO delivering a 34.3% surge to $437.7 million. Q4 2024 alone saw a 40.8% revenue increase.
• Operating leverage: The company reported a GAAP operating loss of just $2.5 million for 2024—down significantly from prior years—alongside a robust non-GAAP operating profit of $62.9 million, highlighting a rapid pathway to profitability.
• Forward guidance: Management’s 2025 revenue outlook was revised upwards, now projecting $560–$575 million total revenues and $535–$550 million for ORLADEYO alone. This guidance aligns with a projected 20%+ annual CAGR over the next three years.
• Valuation: While BioCryst’s trailing P/E is not applicable due to transitional losses, the forward P/E of 62.11 and P/S of 4.52 are increasingly attractive given sector growth rates and high-margin expansion potential. Analyst consensus targets a price of $16.58 (+52% upside), within a bullish $11–$30 range.
• Strategic leadership and specialisation: BioCryst’s innovative platform, centering around structure-guided drug design, confers defensible barriers and maintains the company’s global standing in rare disease therapeutics—particularly hereditary angioedema (HAE).

Importantly, this growth is not built on hype but on a foundation of expanding market opportunity, efficient capital deployment, and a disciplined pathway to profitability.

Volume and Liquidity

• Average three-month volume: 97.34 million shares
• Shares outstanding: 209.25 million

Such heavy daily turnover—and an accessible float—support efficient price discovery and underscore that BioCryst’s revaluation is grounded in broad, durable market participation, not merely sporadic speculative activity. This liquidity is particularly vital for IE-based and European investors seeking to allocate or rebalance swiftly in US-listed biotech equities.

Moreover, the stock’s moderate beta (1.08 over 5 years) offers a blend of growth exposure and manageable volatility within a typically high-beta sector, making it attractive for those managing portfolio risk.

Catalysts and Positive Outlook

• ORLADEYO pediatric extension: A major NDA submission is planned for 2025, aiming to make ORLADEYO the first targeted, oral prophylactic option for children aged 2–11 with HAE—a potentially game-changing expansion in patient reach.
• R&D pipeline momentum: With two promising assets—BCX17725 in Netherton syndrome (Phase 1) and Avoralstat for diabetic macular edema—clinical readouts due by year-end 2025 could unlock significant new value.
• Geographic and reimbursement expansion: ORLADEYO is now reimbursed across all major Western European markets (except the Netherlands), broadening revenue durability and reducing regional regulatory uncertainty.
• Imminent profitability: Management projects a pivotal transition to positive EPS and cash flow in the second half of 2025, a milestone likely to attract a broader institutional audience.

These catalysts align with supportive industry dynamics:

• Heightened regulatory priority for rare/orphan diseases
• Patient demand for effective, orally delivered therapies
• Global recognition of unmet needs in genetic conditions

BioCryst’s unique positioning as the leading provider of oral HAE therapy is a core structural strength, with its scientific and commercial acumen increasingly recognised both in the US and EU markets, including Ireland.

Investment Strategies

From a strategic allocation perspective, BioCryst presents notable arguments for short, medium, and long-term positioning:

• Short-term:
• The stock is trading just above a key support and about to test resistance—momentum-driven traders could capitalise on bullish technical signals, especially with the MACD and moving averages in alignment.
• Anticipation of incremental news on the pediatric NDA or early clinical data could trigger volatility to the upside.
• Medium-term:
• With the sector’s optimism, consistent volume, and positive annual guidance revisions, BCRX seems well-positioned for investors seeking multi-quarter gains and a play on continued biotech sector outperformance.
• Long-term:
• Investors with longer horizons may find the transition to profitability, expanding pipeline, and diversification of revenue (pending successful development of BCX17725 and Avoralstat) to be particularly compelling.
• A leading first-mover advantage in a high-growth rare disease category could yield outsized returns as BioCryst cements its competitive moat.

Entry at current technical levels—well supported, just ahead of prospective catalysts—seems to represent an excellent opportunity for portfolio addition, especially for those looking to benefit from potential new high ground as the company enters its next growth phase.

Is It the Right Time to Buy BioCryst?

• Accelerating revenue growth with clear visibility into future sales
• Imminent operational profitability and a rapidly improving balance sheet
• Strong volume and liquidity, reflecting institutional endorsement
• Technically robust support, positive momentum, and upside targets well above current levels
• Multiple near-term catalysts, including pivotal regulatory events and transformative pipeline developments

Against the backdrop of a buoyant biotech sector and a growing focus on innovative, orally delivered rare disease therapeutics—especially across the European and Irish healthcare landscape—the fundamentals of BioCryst unequivocally justify renewed interest. The share’s recent consolidation above key support, and resolute breaking of resistance, suggest the stock may be entering a new bullish phase as it approaches important operational inflection points.

For investors seeking exposure to a company with demonstrable growth, strategic differentiation, and a robust pipeline, BioCryst seems to represent an excellent opportunity at an opportune time. The convergence of technical strength, fundamental momentum, and compelling catalysts positions the stock squarely as one worth a serious look in any forward-thinking biotechnology or healthcare portfolio.

The coming months could prove defining for BioCryst’s trajectory within the sector—and for those attuned to its emerging strengths, the current entry point appears exceptionally favourable for capturing both near- and long-term upside potential.

How to buy BioCryst stock in Ireland?

Buying BioCryst Pharmaceuticals (BCRX) stock online is a simple, secure process when you use a regulated broker based in Ireland or the EU. Investors have two main approaches: you can buy shares directly (spot/cash buying), owning them outright, or trade using Contracts for Difference (CFDs), which allow you to speculate on price movements with leverage, but without owning the actual shares. Both methods are accessible via reliable platforms and protect buyers through strict European regulations. For a breakdown of the most competitive brokers and their fees, see the comparison table further down this page.

Spot Buying

A cash or spot purchase means you acquire actual BioCryst shares in your brokerage account, becoming a shareholder with all associated rights. Fees for Irish investors typically consist of a fixed commission per order — generally in the €4-€8 range, often converted automatically from dollar trades. For example, with BioCryst trading at $10.88 per share, investing $1,000 (about €920) allows you to buy approximately 91 shares (taking a $5 brokerage fee into account).

Informations importantes

Gain scenario: If the BioCryst share price increases by 10%, the value of your investment rises to $1,100.
Result: A gross gain of $100, or +10% on your invested amount (before taxes and fees).

Trading via CFD

CFD trading lets you speculate on BioCryst’s share price without owning the actual securities. CFDs are derivative contracts where you profit from the difference in price, either up or down. Brokers typically charge a “spread” (the difference between buying and selling prices) and, if you hold positions overnight, a small daily financing fee. If you decide to trade with $1,000 and use 5x leverage, you control $5,000 worth of BCRX exposure.

Informations importantes

Gain scenario: Should BioCryst shares rise by 8%, your CFD position delivers 8% × 5 = 40% return.
Result: That’s a $400 gross gain on your $1,000 stake (not accounting for spreads and overnight fees).

Final Advice

Before investing, take time to compare each broker’s charges and conditions—commission structure, currency conversion costs, available platforms, and support. Whether you prefer traditional share ownership or more active CFD trading depends on your strategy and experience level. The right choice hinges on your goals and risk appetite; use our detailed broker comparison further down the page to pinpoint the provider that best fits your needs. Investing online in BioCryst is accessible and secure, provided you start with good preparation and sound choices.

Our 7 tips for buying BioCryst stock

The latest news about BioCryst

BioCryst stock surged over 8% in the past week, outperforming peers on strong buying signals. The share price climbed to $10.88 with continued positive momentum, reflecting a 8.04% weekly gain and an impressive 76.91% advance over the past year. These trends are supported by robust technical indicators, including all major moving averages (20, 50, 100, and 200 days) issuing buy signals, and a MACD that further underscores market optimism. This technical strength points to an ongoing bullish sentiment, which is particularly relevant for investors and financial analysts based in Ireland seeking momentum-driven opportunities on the NASDAQ biotechnology segment.

BioCryst’s European headquarters in Dublin underscores its strategic commitment and operational footprint in Ireland. Having established its EU base in the Irish capital, BioCryst is well placed to manage its European operations efficiently and to engage proactively with key healthcare and regulatory stakeholders. This presence facilitates not only direct market access for flagship products like ORLADEYO but also positions Ireland as a gateway for further expansion across major Western European markets where reimbursement for ORLADEYO is now secured, benefiting Irish patients and healthcare infrastructure.

Strong revenue growth and raised full-year guidance highlight improving fundamentals and future potential. Total revenues for Q4 2024 saw a yearly increase of over 40%, with full-year 2024 revenues reaching $450.7 million, up 36% year-on-year. Notably, projections for 2025 have been revised upwards, with anticipated ORLADEYO revenues of $535-$550 million, reflecting sustained demand and expanded market coverage. Although currently reporting a net loss, the company achieved a positive non-GAAP operating income of $62.9 million in 2024, and is approaching both earnings-per-share and cash-flow break-even—the latter expected in the second half of 2025. This trajectory strengthens confidence in BioCryst as a growth name for Irish investors and portfolio managers focused on the healthcare sector.

ORLADEYO’s reimbursement status across Western Europe, including Ireland, is a significant commercial milestone. With reimbursement now secured in all major Western European markets except the Netherlands, Irish patients with hereditary angioedema (HAE) gain access to the only oral prophylactic therapy of its kind. This enhances local patient care, supports continued revenue growth from Irish and European sales, and demonstrates BioCryst's ongoing engagement with the Irish Health Service Executive and other regional payers. Access to innovative therapies remains a key consideration for Ireland’s biopharmaceutical ecosystem and health authorities.

Upcoming pipeline milestones, including pediatric expansion and new clinical data in 2025, present further upside. The company is advancing the regulatory submission for pediatric use of ORLADEYO, with FDA acceptance targeted for 2025, potentially broadening the addressable market and reinforcing its leadership in HAE therapy. Additionally, clinical results are expected later this year for BCX17725 (Netherton syndrome) and Avoralstat (diabetic macular edema), which, if positive, could diversify company revenues and risk profile. For the Irish investor community, such innovation and pipeline progress underline BioCryst’s capacity for long-term value creation and scientific leadership within Europe.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.